We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Whilst it’s varied over time, NICE has been getting faster at publishing final Single Technology Appraisal (STA) guidance (see figure 1). The most recent public data available from the ...

Omnicell Inc. (OMCL) reported its first-quarter 2025 earnings, exceeding Wall Street’s expectations with an earnings per share (EPS) of $0.26, surpassing the forecasted $0.21. Despite this ...

And it’s also abundantly clear, as it has been for years, that you can be as nice as you want to Donald Trump, but he’ll still aim for your shins as you walk out the door.

Sitting in the southeast corner of France along the Mediterranean Sea, Nice is best known as a beach destination. However, those who take the time to explore the offshore areas of this small city ...

Omnicell Inc. (OMCL) reported its first-quarter 2025 earnings, exceeding Wall Street’s expectations with an earnings per share (EPS) of $0.26, surpassing the forecasted $0.21. Despite this positive ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.